Efficacy and safety of belimumab in lupus nephritis patients: a real-world observational study in China
BACKGROUND: This study aimed to describe disease activity, clinical outcome and overall patterns of lupus nephritis care in patients who received belimumab in a real-world clinical setting in China. MATERIALS AND METHODS: This observational cohort study included lupus nephritis patients who received...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2023-02-01
|
| Series: | Kidney Diseases |
| Online Access: | https://www.karger.com/Article/FullText/529675 |
| _version_ | 1811157644725977088 |
|---|---|
| author | Meng Tan Jing Xu Ying Tan Zhen Qu Feng Yu Minghui Zhao |
| author_facet | Meng Tan Jing Xu Ying Tan Zhen Qu Feng Yu Minghui Zhao |
| author_sort | Meng Tan |
| collection | DOAJ |
| description | BACKGROUND: This study aimed to describe disease activity, clinical outcome and overall patterns of lupus nephritis care in patients who received belimumab in a real-world clinical setting in China.
MATERIALS AND METHODS: This observational cohort study included lupus nephritis patients who received belimumab as adjunct therapy. We deeply investigated the characteristics of those patients including clinical response to belimumab and safety.
RESULTS: All 61 lupus nephritis patients were included with a median follow-up period of 9 months (6,19). Prevalence of proteinuria (52.5% to 24.6%) and hematuria (33.3% to 9.8%) were decreased with a stable level of eGFR at last visit. The percentage of patients achieved complete or partial renal response increased from 47.5% to 78.7% and the proportion of complete or partial renal response in patients with proliferative lupus nephritis was higher than those with membranous lupus nephritis (75% vs. 50%) at last visit. The median SLEDAI score decreased from 6 to 2, and there was an increase in patient of LLDAS from 17 to 33 at last visit. A notable dose reduction was seen for glucocorticosteroid dose, with a median change from 10 to 5 mg/d. The proportion of patients receiving >7.5 mg/d steroids reduced from 52.5% at baseline to 23.0% at last visit. The discontinuation of belimumab was rare (3/61) for drug induced fever, hyperthyroidism and uveitis.
CONCLUSIONS: Lupus nephritis patients with belimumab demonstrated improvements in clinical response and a reduction in glucocorticosteroids, which providing evidence of effectiveness and safety in real-world clinical practice in China. |
| first_indexed | 2024-04-10T05:10:46Z |
| format | Article |
| id | doaj.art-ac4c57d0942746ec8a2543d159611b7b |
| institution | Directory Open Access Journal |
| issn | 2296-9381 2296-9357 |
| language | English |
| last_indexed | 2024-04-10T05:10:46Z |
| publishDate | 2023-02-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Kidney Diseases |
| spelling | doaj.art-ac4c57d0942746ec8a2543d159611b7b2023-03-09T08:59:36ZengKarger PublishersKidney Diseases2296-93812296-93572023-02-011110.1159/000529675529675Efficacy and safety of belimumab in lupus nephritis patients: a real-world observational study in ChinaMeng Tanhttps://orcid.org/0000-0003-1532-7922Jing XuYing Tanhttps://orcid.org/0000-0002-8139-5758Zhen Quhttps://orcid.org/0000-0001-9492-1078Feng YuMinghui ZhaoBACKGROUND: This study aimed to describe disease activity, clinical outcome and overall patterns of lupus nephritis care in patients who received belimumab in a real-world clinical setting in China. MATERIALS AND METHODS: This observational cohort study included lupus nephritis patients who received belimumab as adjunct therapy. We deeply investigated the characteristics of those patients including clinical response to belimumab and safety. RESULTS: All 61 lupus nephritis patients were included with a median follow-up period of 9 months (6,19). Prevalence of proteinuria (52.5% to 24.6%) and hematuria (33.3% to 9.8%) were decreased with a stable level of eGFR at last visit. The percentage of patients achieved complete or partial renal response increased from 47.5% to 78.7% and the proportion of complete or partial renal response in patients with proliferative lupus nephritis was higher than those with membranous lupus nephritis (75% vs. 50%) at last visit. The median SLEDAI score decreased from 6 to 2, and there was an increase in patient of LLDAS from 17 to 33 at last visit. A notable dose reduction was seen for glucocorticosteroid dose, with a median change from 10 to 5 mg/d. The proportion of patients receiving >7.5 mg/d steroids reduced from 52.5% at baseline to 23.0% at last visit. The discontinuation of belimumab was rare (3/61) for drug induced fever, hyperthyroidism and uveitis. CONCLUSIONS: Lupus nephritis patients with belimumab demonstrated improvements in clinical response and a reduction in glucocorticosteroids, which providing evidence of effectiveness and safety in real-world clinical practice in China.https://www.karger.com/Article/FullText/529675 |
| spellingShingle | Meng Tan Jing Xu Ying Tan Zhen Qu Feng Yu Minghui Zhao Efficacy and safety of belimumab in lupus nephritis patients: a real-world observational study in China Kidney Diseases |
| title | Efficacy and safety of belimumab in lupus nephritis patients: a real-world observational study in China |
| title_full | Efficacy and safety of belimumab in lupus nephritis patients: a real-world observational study in China |
| title_fullStr | Efficacy and safety of belimumab in lupus nephritis patients: a real-world observational study in China |
| title_full_unstemmed | Efficacy and safety of belimumab in lupus nephritis patients: a real-world observational study in China |
| title_short | Efficacy and safety of belimumab in lupus nephritis patients: a real-world observational study in China |
| title_sort | efficacy and safety of belimumab in lupus nephritis patients a real world observational study in china |
| url | https://www.karger.com/Article/FullText/529675 |
| work_keys_str_mv | AT mengtan efficacyandsafetyofbelimumabinlupusnephritispatientsarealworldobservationalstudyinchina AT jingxu efficacyandsafetyofbelimumabinlupusnephritispatientsarealworldobservationalstudyinchina AT yingtan efficacyandsafetyofbelimumabinlupusnephritispatientsarealworldobservationalstudyinchina AT zhenqu efficacyandsafetyofbelimumabinlupusnephritispatientsarealworldobservationalstudyinchina AT fengyu efficacyandsafetyofbelimumabinlupusnephritispatientsarealworldobservationalstudyinchina AT minghuizhao efficacyandsafetyofbelimumabinlupusnephritispatientsarealworldobservationalstudyinchina |